People want to know which type of herpes they have because they think the type tells them how bad it will be. It is part of the picture. The bigger factor is site: where the virus set up, oral or genital. Type and site together predict how often you will get outbreaks, and that prediction is the thing that should drive treatment decisions. Here is how it actually works.

The old rule is broken

The textbook version used to be simple. HSV-1 causes cold sores on the mouth. HSV-2 causes genital herpes. That split was never absolute and it is less true every year. Both viruses can infect either site. Oral-genital contact moves HSV-1 to the genitals, and genital HSV-1 is now a large and rising share of new genital herpes diagnoses, especially in younger people.

So knowing your type alone does not tell you where the virus is or how it will behave. You need both pieces.

Recurrence is driven by the combination of type and site

This is the part that actually matters for daily life, and the numbers are striking.

Genital HSV-2 is the most recurrence-prone combination. In natural-history studies, about 89 percent of people with genital HSV-2 had at least one recurrence during follow-up, roughly 38 percent had six or more in the first year, and about 20 percent had more than ten (Benedetti et al., Ann Intern Med 1994). The median was around four recurrences in the first year.

Genital HSV-1 is much quieter. The overall recurrence rate in the first year is around 1.3, and roughly 43 percent of people have no recurrence at all in that first year (Engelberg et al.). In older comparative data, only about 14 percent of genital HSV-1 infections recurred versus about 60 percent of genital HSV-2 infections.

Oral HSV-1 (cold sores) recurs in many people but usually a few times a year at most, and a substantial fraction get few or no recurrences.

Oral HSV-2 is uncommon and tends to recur rarely.

The pattern: HSV-2 likes to live in genital tissue and reactivates there often. HSV-1 likes to live in oral tissue and is relatively dormant when it ends up genitally. Same virus families, very different behavior depending on the match between type and location.

Shedding follows the same logic

Asymptomatic shedding (when the virus is on the skin and transmissible without any symptoms) tracks recurrence. Genital HSV-2 sheds the most. Genital HSV-1 sheds less, and the shedding declines over time after the first infection (UW Medicine). This matters for transmission risk, which is highest with genital HSV-2 and lower with genital HSV-1.

What this means for treatment

The type-and-site combination changes the calculus on daily suppressive therapy versus episodic treatment.

  • Genital HSV-2 with frequent outbreaks is the classic candidate for daily suppression. High recurrence and high shedding give daily antiviral the most to work with.
  • Genital HSV-1, because it recurs and sheds so much less, often does fine with episodic treatment or no routine medication at all. Many people with genital HSV-1 have one notable first episode and little after.
  • Oral HSV-1 is usually handled episodically. Daily suppression is reserved for people with frequent or disabling cold sores.

The drug is the same across all of these. Valacyclovir and acyclovir work on both types. What changes is how aggressively you need to use them.

A note on testing and labels

Blood antibody tests (type-specific IgG) can tell you whether you carry HSV-1, HSV-2, or both. They have real limits. They do not tell you the anatomic site, so a positive HSV-1 result could reflect an old oral infection you have had since childhood and says nothing about your genitals. Low-positive HSV-2 results can be false positives from cross-reactivity and should be confirmed before you are labeled. And the tests miss a meaningful fraction of true infections.

For these reasons the CDC and USPSTF do not recommend routine herpes blood-test screening of people without symptoms (USPSTF). A swab of an active sore (PCR or culture) is the better test when you have a lesion, because it confirms the infection and gives you the type at the same time.

The bottom line

Type matters, but site matters more, and the two together are what predict your experience. Genital HSV-2 is the most active combination and the one most likely to warrant daily treatment. Genital HSV-1 is usually mild. Knowing both your type and your site lets you and a clinician match the treatment to the actual behavior of your infection instead of to a fear.

Medically reviewed by: [Reviewer name, credentials] — [Date]

Not sure what your type and site mean for you? A licensed clinician can review your test results and outbreak history and lay out your options. Start an online visit.

This article is for general education and is not a substitute for personalized medical advice from a licensed clinician.